Seven days triple therapy for eradication of does not alter the disease activity of patients with inflammatory bowel disease
Background/Aims The influences of Helicobacter pylori eradication therapy on the disease course of inflammatory bowel disease (IBD) are still unclear. We therefore conducted a multicenter, retrospective cohort study to evaluate the safety of H. pylori eradication therapy for IBD patients. Methods IB...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Korean Association for the Study of Intestinal Diseases
2018-10-01
|
| Series: | Intestinal Research |
| Subjects: | |
| Online Access: | http://www.irjournal.org/upload/pdf/ir-2018-00044.pdf |
| _version_ | 1828306712355930112 |
|---|---|
| author | Shinichiro Shinzaki Toshimitsu Fujii Shigeki Bamba Maiko Ogawa Taku Kobayashi Masahide Oshita Hiroki Tanaka Keiji Ozeki Sakuma Takahashi Hiroki Kitamoto Kazuhito Kani Sohachi Nanjo Takeshi Sugaya Yuko Sakakibara Toshihiro Inokuchi Kazuki Kakimoto Akihiro Yamada Hisae Yasuhara Yoko Yokoyama Takuya Yoshino Akira Matsui Misaki Nakamura Taku Tomizawa Ryosuke Sakemi Noriko Kamata Toshifumi Hibi |
| author_facet | Shinichiro Shinzaki Toshimitsu Fujii Shigeki Bamba Maiko Ogawa Taku Kobayashi Masahide Oshita Hiroki Tanaka Keiji Ozeki Sakuma Takahashi Hiroki Kitamoto Kazuhito Kani Sohachi Nanjo Takeshi Sugaya Yuko Sakakibara Toshihiro Inokuchi Kazuki Kakimoto Akihiro Yamada Hisae Yasuhara Yoko Yokoyama Takuya Yoshino Akira Matsui Misaki Nakamura Taku Tomizawa Ryosuke Sakemi Noriko Kamata Toshifumi Hibi |
| author_sort | Shinichiro Shinzaki |
| collection | DOAJ |
| description | Background/Aims The influences of Helicobacter pylori eradication therapy on the disease course of inflammatory bowel disease (IBD) are still unclear. We therefore conducted a multicenter, retrospective cohort study to evaluate the safety of H. pylori eradication therapy for IBD patients. Methods IBD patients with H. pylori eradication from 2005 to 2015 (eradication group) and control patients (non-eradication group; 2 paired IBD patients without H. pylori eradication matched with each eradicated patient) were included. IBD exacerbation (increased/additional IBD drug or IBD-associated hospitalization/surgery) and disease improvement based on the physicians’ global assessment were investigated at baseline, and at 2 and 6 months after eradication or observation. Results A total of 429 IBD (378 ulcerative colitis, 51 Crohn’s disease) patients, comprising 144 patients in the eradication group and 285 patients in the non-eradication group, were enrolled at 25 institutions. IBD exacerbation was comparable between groups (eradication group: 8.3% at 2 months [odds ratio, 1.76; 95% confidence interval, 0.78–3.92; P=0.170], 11.8% at 6 months [odds ratio, 1.60; 95% confidence interval, 0.81–3.11; P=0.172]). Based on the physicians’ global assessment at 2 months, none of the patients in the eradication group improved, whereas 3.2% of the patients in the non-eradication group improved (P=0.019). Multivariate analysis revealed that active disease at baseline, but not H. pylori eradication, was an independent factor for IBD exacerbation during 2 months’ observation period. The overall eradication rate was 84.0%–comparable to previous reports in non-IBD patients. Conclusions H. pylori eradication therapy does not alter the short-term disease activity of IBD. |
| first_indexed | 2024-04-13T14:46:51Z |
| format | Article |
| id | doaj.art-3e886c3f695e421fb91d56212f82f76d |
| institution | Directory Open Access Journal |
| issn | 1598-9100 2288-1956 |
| language | English |
| last_indexed | 2024-04-13T14:46:51Z |
| publishDate | 2018-10-01 |
| publisher | Korean Association for the Study of Intestinal Diseases |
| record_format | Article |
| series | Intestinal Research |
| spelling | doaj.art-3e886c3f695e421fb91d56212f82f76d2022-12-22T02:42:43ZengKorean Association for the Study of Intestinal DiseasesIntestinal Research1598-91002288-19562018-10-0116460961810.5217/ir.2018.00044713Seven days triple therapy for eradication of does not alter the disease activity of patients with inflammatory bowel diseaseShinichiro Shinzaki0Toshimitsu Fujii1Shigeki Bamba2Maiko Ogawa3Taku Kobayashi4Masahide Oshita5Hiroki Tanaka6Keiji Ozeki7Sakuma Takahashi8Hiroki Kitamoto9Kazuhito Kani10Sohachi Nanjo11Takeshi Sugaya12Yuko Sakakibara13Toshihiro Inokuchi14Kazuki Kakimoto15Akihiro Yamada16Hisae Yasuhara17Yoko Yokoyama18Takuya Yoshino19Akira Matsui20Misaki Nakamura21Taku Tomizawa22Ryosuke Sakemi23Noriko Kamata24Toshifumi Hibi25 Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Japan Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan Department of Medicine, Shiga University of Medical Science, Otsu, Japan Department of Gastroenterology and Hepatology, The Jikei University School of Medicine Katsushika Medical Center, Tokyo, Japan Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan Department of Internal Medicine, Osaka Police Hospital, Osaka, Japan IBD Center, Sapporo Kosei General Hospital, Sapporo, Japan Departments of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan Department of Gastroenterology, Kagawa Prefectural Central Hospital, Takamatsu, Japan Department of Gastroenterology and Hepatology, Kobe City Medical Center General Hospital, Kobe, Japan Department of Gastroenterology and Hepatology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan Department of Gastroenterology and Hematology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan Department of Gastroenterology, Dokkyo Medical University, Mibu, Japan Department of Gastroenterology, National Hospital Organization Osaka National Hospital, Osaka, Japan Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan Second Department of Internal Medicine, Osaka Medical College, Takatsuki, Japan Department of Internal Medicine, Toho University Sakura Medical Center, Sakura, Japan Department of Gastroenterology, Mitoyo General Hospital, Kanonji, Japan Department of Inflammatory Bowel Disease, Division of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan Division of Inflammatory Bowel Disease, Digestive Disease Center, Kitano Hospital, Osaka, Japan Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan Department of Gastroenterology and Hepatology, Mie University Graduate School of Medicine, Tsu, Japan Department of Gastroenterology and Hepatology, Gunma University, Maebashi, Japan Department of Gastroenterology, Tobata Kyoritsu Hospital, Kitakyushu, Japan Department of Gastroenterology, Osaka City University Graduate School of Medicine, Osaka, Japan Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, JapanBackground/Aims The influences of Helicobacter pylori eradication therapy on the disease course of inflammatory bowel disease (IBD) are still unclear. We therefore conducted a multicenter, retrospective cohort study to evaluate the safety of H. pylori eradication therapy for IBD patients. Methods IBD patients with H. pylori eradication from 2005 to 2015 (eradication group) and control patients (non-eradication group; 2 paired IBD patients without H. pylori eradication matched with each eradicated patient) were included. IBD exacerbation (increased/additional IBD drug or IBD-associated hospitalization/surgery) and disease improvement based on the physicians’ global assessment were investigated at baseline, and at 2 and 6 months after eradication or observation. Results A total of 429 IBD (378 ulcerative colitis, 51 Crohn’s disease) patients, comprising 144 patients in the eradication group and 285 patients in the non-eradication group, were enrolled at 25 institutions. IBD exacerbation was comparable between groups (eradication group: 8.3% at 2 months [odds ratio, 1.76; 95% confidence interval, 0.78–3.92; P=0.170], 11.8% at 6 months [odds ratio, 1.60; 95% confidence interval, 0.81–3.11; P=0.172]). Based on the physicians’ global assessment at 2 months, none of the patients in the eradication group improved, whereas 3.2% of the patients in the non-eradication group improved (P=0.019). Multivariate analysis revealed that active disease at baseline, but not H. pylori eradication, was an independent factor for IBD exacerbation during 2 months’ observation period. The overall eradication rate was 84.0%–comparable to previous reports in non-IBD patients. Conclusions H. pylori eradication therapy does not alter the short-term disease activity of IBD.http://www.irjournal.org/upload/pdf/ir-2018-00044.pdf eradicationProton pump inhibitorClarithromycinMetronidazole |
| spellingShingle | Shinichiro Shinzaki Toshimitsu Fujii Shigeki Bamba Maiko Ogawa Taku Kobayashi Masahide Oshita Hiroki Tanaka Keiji Ozeki Sakuma Takahashi Hiroki Kitamoto Kazuhito Kani Sohachi Nanjo Takeshi Sugaya Yuko Sakakibara Toshihiro Inokuchi Kazuki Kakimoto Akihiro Yamada Hisae Yasuhara Yoko Yokoyama Takuya Yoshino Akira Matsui Misaki Nakamura Taku Tomizawa Ryosuke Sakemi Noriko Kamata Toshifumi Hibi Seven days triple therapy for eradication of does not alter the disease activity of patients with inflammatory bowel disease Intestinal Research eradication Proton pump inhibitor Clarithromycin Metronidazole |
| title | Seven days triple therapy for eradication of does not alter the disease activity of patients with inflammatory bowel disease |
| title_full | Seven days triple therapy for eradication of does not alter the disease activity of patients with inflammatory bowel disease |
| title_fullStr | Seven days triple therapy for eradication of does not alter the disease activity of patients with inflammatory bowel disease |
| title_full_unstemmed | Seven days triple therapy for eradication of does not alter the disease activity of patients with inflammatory bowel disease |
| title_short | Seven days triple therapy for eradication of does not alter the disease activity of patients with inflammatory bowel disease |
| title_sort | seven days triple therapy for eradication of does not alter the disease activity of patients with inflammatory bowel disease |
| topic | eradication Proton pump inhibitor Clarithromycin Metronidazole |
| url | http://www.irjournal.org/upload/pdf/ir-2018-00044.pdf |
| work_keys_str_mv | AT shinichiroshinzaki sevendaystripletherapyforeradicationofdoesnotalterthediseaseactivityofpatientswithinflammatoryboweldisease AT toshimitsufujii sevendaystripletherapyforeradicationofdoesnotalterthediseaseactivityofpatientswithinflammatoryboweldisease AT shigekibamba sevendaystripletherapyforeradicationofdoesnotalterthediseaseactivityofpatientswithinflammatoryboweldisease AT maikoogawa sevendaystripletherapyforeradicationofdoesnotalterthediseaseactivityofpatientswithinflammatoryboweldisease AT takukobayashi sevendaystripletherapyforeradicationofdoesnotalterthediseaseactivityofpatientswithinflammatoryboweldisease AT masahideoshita sevendaystripletherapyforeradicationofdoesnotalterthediseaseactivityofpatientswithinflammatoryboweldisease AT hirokitanaka sevendaystripletherapyforeradicationofdoesnotalterthediseaseactivityofpatientswithinflammatoryboweldisease AT keijiozeki sevendaystripletherapyforeradicationofdoesnotalterthediseaseactivityofpatientswithinflammatoryboweldisease AT sakumatakahashi sevendaystripletherapyforeradicationofdoesnotalterthediseaseactivityofpatientswithinflammatoryboweldisease AT hirokikitamoto sevendaystripletherapyforeradicationofdoesnotalterthediseaseactivityofpatientswithinflammatoryboweldisease AT kazuhitokani sevendaystripletherapyforeradicationofdoesnotalterthediseaseactivityofpatientswithinflammatoryboweldisease AT sohachinanjo sevendaystripletherapyforeradicationofdoesnotalterthediseaseactivityofpatientswithinflammatoryboweldisease AT takeshisugaya sevendaystripletherapyforeradicationofdoesnotalterthediseaseactivityofpatientswithinflammatoryboweldisease AT yukosakakibara sevendaystripletherapyforeradicationofdoesnotalterthediseaseactivityofpatientswithinflammatoryboweldisease AT toshihiroinokuchi sevendaystripletherapyforeradicationofdoesnotalterthediseaseactivityofpatientswithinflammatoryboweldisease AT kazukikakimoto sevendaystripletherapyforeradicationofdoesnotalterthediseaseactivityofpatientswithinflammatoryboweldisease AT akihiroyamada sevendaystripletherapyforeradicationofdoesnotalterthediseaseactivityofpatientswithinflammatoryboweldisease AT hisaeyasuhara sevendaystripletherapyforeradicationofdoesnotalterthediseaseactivityofpatientswithinflammatoryboweldisease AT yokoyokoyama sevendaystripletherapyforeradicationofdoesnotalterthediseaseactivityofpatientswithinflammatoryboweldisease AT takuyayoshino sevendaystripletherapyforeradicationofdoesnotalterthediseaseactivityofpatientswithinflammatoryboweldisease AT akiramatsui sevendaystripletherapyforeradicationofdoesnotalterthediseaseactivityofpatientswithinflammatoryboweldisease AT misakinakamura sevendaystripletherapyforeradicationofdoesnotalterthediseaseactivityofpatientswithinflammatoryboweldisease AT takutomizawa sevendaystripletherapyforeradicationofdoesnotalterthediseaseactivityofpatientswithinflammatoryboweldisease AT ryosukesakemi sevendaystripletherapyforeradicationofdoesnotalterthediseaseactivityofpatientswithinflammatoryboweldisease AT norikokamata sevendaystripletherapyforeradicationofdoesnotalterthediseaseactivityofpatientswithinflammatoryboweldisease AT toshifumihibi sevendaystripletherapyforeradicationofdoesnotalterthediseaseactivityofpatientswithinflammatoryboweldisease |